These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 25548535)

  • 1. What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?
    Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH
    Exp Neurobiol; 2014 Dec; 23(4):352-64. PubMed ID: 25548535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease.
    Kang JH
    J Mov Disord; 2016 May; 9(2):89-96. PubMed ID: 27240810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.
    Johar I; Mollenhauer B; Aarsland D
    Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers.
    Farotti L; Paolini Paoletti F; Simoni S; Parnetti L
    Biomark Insights; 2020; 15():1177271920964077. PubMed ID: 33110345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges.
    Kim D; Kim YS; Shin DW; Park CS; Kang JH
    J Clin Neurol; 2016 Oct; 12(4):381-392. PubMed ID: 27819412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
    Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
    Atik A; Stewart T; Zhang J
    Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.
    Farotti L; Paciotti S; Tasegian A; Eusebi P; Parnetti L
    Expert Rev Mol Diagn; 2017 Aug; 17(8):771-780. PubMed ID: 28604235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
    Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Singleton A; Shaw LM; Trojanowski JQ; Frasier M; Simuni T; Iranzo A; Oertel W; Siderowf A; Weintraub D; Seibyl J; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Marek K; Galasko D;
    Mov Disord; 2019 Sep; 34(9):1354-1364. PubMed ID: 31361367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should we be using biomarkers in trials of disease modification in Parkinson's disease?
    Vijiaratnam N; Foltynie T
    Brain; 2023 Dec; 146(12):4845-4869. PubMed ID: 37536279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.
    Majbour NK; Vaikath NN; Eusebi P; Chiasserini D; Ardah M; Varghese S; Haque ME; Tokuda T; Auinger P; Calabresi P; Parnetti L; El-Agnaf OM
    Mov Disord; 2016 Oct; 31(10):1535-1542. PubMed ID: 27548849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Alzheimer's genetic risk scores and CSF biomarkers in de novo Parkinson's Disease.
    Lee YG; Jeong SH; Park M; Kang SW; Baik K; Jeon S; Lee PH; Sohn YH; Ye BS
    NPJ Parkinsons Dis; 2022 May; 8(1):57. PubMed ID: 35545633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis.
    Eusebi P; Hansson O; Paciotti S; Orso M; Chiasserini D; Calabresi P; Blennow K; Parnetti L
    BMJ Open; 2017 Nov; 7(11):e018177. PubMed ID: 29170290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.